GERONTOLOGICAL SOCIETY OF AMERICA

www.geron.org

1220 L Street, NW, Suite 901, Washington, DC 20005-4018 • Ph. 202-842-1275, fax 202-842-1150, email: geron@geron.org



Grand Hyatt ● Washington, DC Wednesday and Thursday, October 16-17, 2013

Program Agenda

The October 2013 National Summit on OTC Sleep Aids and Sleep Health in Older Adults will be a full-day conference in Washington, DC. The Summit is intended to raise understanding of issues and risks related to OTC sleep aid use in older adults, and frame future efforts to address barriers affecting health care professionals, older adults, and caregivers. Stakeholders convening for the Summit draw from the public and private sectors; trade, professional, and advocacy organizations; and academia. Thought leaders with varied interests, experience, and expertise in OTC sleep aids and sleep health in older adults will be participating. The Summit is an effort of The Gerontological Society of America (GSA) and supported by Pfizer.

Objectives of the 2013 National Summit on OTC Sleep Aids and Sleep Health in Older Adults

- Increase understanding of sleep health and OTC sleep aid use in older adults (ages 65 years and older).
- Identify opportunities for improving understanding among health care practitioners, consumers, and caregivers regarding use of OTC sleep aids in older adults.
- Enable networking to create new connections and deepen existing relationships with individuals having a common interest in older adult sleep health and sleep aid use.

WEDNESDAY, OCTOBER 16, 2013

6:00 PM-8:00 PM **Registration and Networking Reception** *Grand Hyatt—Cabin John Room*


THURSDAY, OCTOBER 17, 2013


7:00 am-8:00 am	Registration and Breakfast Grand Hyatt— Wilson Room
8:00 am–8:30 am	Welcome and Why We Are Here Grand Hyatt—Constitution Rooms D/E James C. Appleby, RPh, MPH, Executive Director and CEO The Gerontological Society of America
	Annette Schmidt, Senior Director of Strategic Alliances and Business Development


The Gerontological Society of America

8:30 am–9:45 am	Introduction of the Workgroup, Stakeholders, and the Goals for the Day Steven M. Albert, PhD, <i>Workgroup Chairperson</i> Professor and Chair, Department of Behavioral and Community Health Sciences Graduate School of Public Health, University of Pittsburgh
9:45 am-11:00 am	Uncovering Stakeholder Experience and Perception Regarding OTC Sleep Aids and Sleep Health in Older Adults Facilitator: Judy Klein
	 Participants will work in small groups to kick-start engagement in discussions and networking by using "investigative journalism" techniques to address the following questions: What are 3 to 5 key reasons or benefits relevant to you or your organization for improving sleep health in older adults? What do you believe to be the key issues older adults face on OTC sleep aid use? What are the greatest barriers you face in your organization to support improved OTC sleep aid use in older adults? What are 3 to 5 key ways you or your organization could contribute to achieve safe use of OTC sleep aids in older adults?
11:00 ам-11:15 ам	Wiggle Break
11:15 ам–12:30 рм	State of Knowledge About Sleep Health in Older Adults Speaker: Phyllis Zee, MD, PhD Professor of Neurology, Neurobiology, and Physiology Director, Sleep Disorders Center Northwestern University Roundtable groups will discuss questions posed by Dr. Zee and share their top 1 to 2 themes
	and/or surprises uncovered.
12:30 рм — 1:00 рм	Networking Lunch Grand Hyatt—Wilson Room
1:00 pm-2:00 pm	State of Knowledge About OTC Sleep Aid Use by Older Adults Speaker: Thomas Roth, PhD Director of Research and Division Head Sleep Disorders and Research Center Henry Ford Health System
	Roundtable groups will discuss questions posed by Dr. Roth and share their top 1 to 2 themes and/or surprises uncovered.
2:00 рм–3:00 рм	Call to Action to Improve Safe Use of OTC Sleep Aids—Now and in the Future Moderator: Steven M. Albert, PhD, <i>Workgroup Chairperson</i> Panel: James A. Owen, PharmD, BCPS; Deborah A. DiGilio, MPH; Joan Enstam Baird, PharmD, CGP, FASCP
	Lively, moderated discussion among panelists representing varied perspectives; includes time for participants to pose thought-provoking questions to panelists.

3:00 рм–3:15 рм	Wiggle Break
3:15 рм–4:45 рм	Prioritize Topics for Future Emphasis Facilitator: Judy Klein
	Participants break out into small groups to develop proposals (<i>posters</i>) for improving older adult sleep health and use of sleep aids. Led by Panel Discussants, Workgroup, and Facilitators.
4:45 pm	Closing Remarks: Reflections of the Day and Next Steps
5:00 pm	Adjournment






























Summit Agen	da	OTE SLEEP ALDS AND SLEEP HEALTH WOLDER HAUUTS
9:45 am – 11:00 am	Uncovering Stakeholder Experience Regarding OTC Sleep Aids and Sleep Adults	•
11:00 ам – 11:15 ам	Wiggle Break	
11:15 ам – 12:30 рм	State of Knowledge About Sleep Hea	alth in Older Adults
12:30 рм – 1:00 рм	Networking Lunch	
1:00 рм — 2:00 рм	State of Knowledge About OTC Sleeı Adults	p Aid Use by Older
2:00 рм — 3:00 рм	Call to Action to Improve Safe Use o Now and in the Future	f OTC Sleep Aids—
3:00 рм – 3:15 рм	Wiggle Break	
3:15 рм – 4:45 рм	Prioritize Topics for Future Emphasis	S
4:45 рм – 5:00 рм	Closing Remarks: Reflections of the	Day and Next Steps



























State of Knowledge About Sleep Health in Older Adults


Phyllis Zee, MD, PhD






















Caregivers		
McCurry and Teri	68%	
Pruchno and Potashnik	22-41% (men), 53-67% (women)	
Wilcox and King	67% (women only)	
Persons with Dementia		
Carpenter et al.	40%	
Craig et al.	42–54%	
Lyketsos et al.	20–27%	
McCurry et al.	35%	
Moran et al.	25%	
Pang, et al.	35–54%	
Rabins	33%	
Ritchie	19–44%	
Thommessen et al.	25%	



















Health Condition	Associated With					
	Sleep Duration	Insomnia	Interaction			
Hypertension ¹	<mark>Yes</mark> (≤ 6 hours)	Yes	Yes			
Type 2 Diabetes ²	No	No	<mark>Yes</mark> (≤ 5 hours)			
Neuropsychological test performance ³	Yes (≤ 6 hours) 5/14 tests	No	Yes 4/14 tests			
Mortality ⁴	No	No	Yes (< 6 hours, Men only)			
Cortisol ⁵	No	Yes	Yes (SE < 70%)			


67


¹Vgontzas AN. *Sleep.* 2009;32:491-497. ²Vgontzas AN. *Diabetes Care.* 2009;32:1980-1985. ³Fernandez-Mendoza J. *Sleep.* 2010;33:459-465. ⁴Vgontzas AN. *Sleep.* 2010;33:1159-1164. ⁵Vgontzas AN. *J Clin Endocrin Metab.* 2001;86:3787-3794.





	Total S	ample	Ages 18	-34 Yrs	Ages 35–59 Yrs		Ages 60)+ Yrs
	Days ^a	(SE)	Days ^a	(SE)	Days ^a	(SE)	Days ^a	(SE)
Insomnia	.42 ^b	(.10)	.12	(.15)	.44 ^b	(.12)	.77 ^b	(.25)
Cardiovascular Disorders								
Hypertension	.25 ^b	(.10)	18	(.25)	.28 ^b	(.14)	.45 ^b	(.20)
Heart disease	.63	(.71)	05	(.23)	-1.74	(2.10)	.51	(.70)
Respiratory Disorders								
Seasonal allergies or hay fever	18 ^b	(.07)	06	(.14)	06	(.08)	66 ^b	(.19)
Chronic bronchitis, emphysema, other	11	(.15)	22	(.12)	34	(.21)	.42	(.38)
COPD	.80 ^b	(.35)	.04	(.24)	17	(.45)	1.12 ^b	(.49)
Musculoskeletal Disorders								
Arthritis (osteo or rheumatoid)	.16	(.14)	20	(.18)	.54 ^b	(.17)	36	(.32)
Back or neck pains	.20 ^b	(.09)	.16	(.20)	.28 ^b	(.10)	.01	(.22)
Other Pain Disorders								
Migraine headaches	.11	(.10)	.05	(.11)	.14	(.16)	.34	(.44)
Other frequent or severe headaches	.19	(.14)	.05	(.16)	.36 ^b	(.16)	.27	(.45)
Chronic pain of any sort including muscle, joint or nerve	.48 ^b	(.09)	.43 ^b	(.17)	.42 ^b	(.10)	.66 ^b	(.25)





Summary







"Worried About Growing Old? Don't Lose Sleep Over It."


- Healthy aging is associated with changes in sleep and circadian rhythms, BUT does not explain the magnitude of sleep problems in aging
- It is the pathological changes in circadian and sleep and co-morbid medical and psychiatric disorders that result in most sleep complaints in the older adult
- Behavioral treatments, such as light and activity, can improve circadian and sleep function-cognition and health in older adults with and without dementia
























Beers Criteria	AND SLEEP HEALTH IN OLDER ADULTS
TABLE 1: 2012 AGS Beers Criteria for Pot	tentially Inappropriate Medication Use in Older Adults
Organ System/ Therapeutic Category/Drug(s)	Recommendation, Pationale, Quality of Evidence (QB) & Strength of Recommendation (SR)
Antichoðnergics (excludes TCAs)	
First-generation anti-his tamines (as single agent or as part of combination products) Brompheniramine Carbinoxamine Chlorpheniramine Cyproheptadine Dexchlorpheniramine Diphenkydramine (oral) Doxylamine Hydroxyzine Promethaa ne Triprolidine	Awoid. Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; increased risk of confu- sion, dry mouth, constipation, and other anticholinergic effects? toxidity. Use of diphenhydramine in special situations such as acute treat- ment of severe allergic reaction may be appropriate. QE = High (Hydroxyzine and Romethazinė), Moderate (All others); SR = Strong
Anti parlins on agents Benztropi ne (oral) Trihexyphenidyl	Awoid. Not recommended for prevention of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. QE = Moderate SR = Strong














	Nur	nber of Da	ys in Last I	Month	
Age	<1	1-4	5-19	20+	
60+	9.1%	24.1%	31.2%	35.6%	
65+	8.3%	24.7%	31.4%	35.6%	
75+	7.4%	19.3%	31.6%	41.7%	








Diphenhydramine	Pharmacokinetics
and Age	



	Elderly Adults	Young Adults	Children
Age* (yrs)	69.4 ± 4.3	31.5 ± 10.4	8.9 ± 1.7
Weight (kg)	71.0 ± 11.4	70.3 ± 9.9	31.6 ± 6.8
Dose (mg)	86.0 ± 7.3	87.9 ± 12.4	39.5 ± 8.4
Cp _{max} (ng/mL)	188.4 ± 54.5	133.2 ± 37.6	81.8 ± 30.2
t _{max} (h)	1.7 ± 0.8	1.7 ± 1.0	1.3 ± 0.5
$t_{1/2}$ (h)	13.5 ± 4.2	9.2 ± 2.5	5.4 ± 1.8
CI (mL/min/kg)	11.7 ± 3.1	23.3 ± 9.4	49.2 ± 22.8
Vd _{ss} (L/kg)	10.2 ± 3.0	14.6 ± 4.0	17.9 ± 5.9
Vd (Lkg)	13.6 ± 6.3	17.4 ± 4.8	21.7 ± 6.6
AUC (ng/mL/h)	1902 ± 572	1031 ± 437	475 ± 137
MRT (h)	14.8 ± 2.8	11.3 ± 3.1	6.4 ± 1.6

• Mean ± standard deviation.

Simons KJ et al. J Clin Pharmacol. 1990;30:665-671.



Diphenhydramine Pharmacokinetics by Age and Sex




	Young Men (n = 10)	Elderly Men (n = 7)	Young Women (n = 10)	Elderly Women (n = 10)
Subject Characteristics				
Age (yrs)	30.4 ± 5.8	64.3 ± 1.8	29.4 ± 2.4	70.1 ± 1.2
Weight (kg)	73.9 ± 2.2	71.9 ± 5.4	65.4 ± 8.7	69.2 ± 3.6
Height (cm)	177.9 ± 1.3	176.0 ± 1.3	166.7 ± 2.2	169.9 ± 1.9
Diphenhydramine Kinetics				
C _{max} (ng/mL)	35.3 ± 4.2	32.4 ± 6.1	34.7 ± 5.9	26.7 ± 2.9
t _{max} (hrs after dose)	2.1 ± 0.4	2.3 ± 0.3	2.2 ± 0.2	2.7 ± 0.3
$t_{1/2}$ (hrs)	4.1 ± 0.3	7.4 ± 3.0	4.4 ± 0.3	4.9 ± 0.6
Total AUC (ng·hr/mL)	192.5 ± 18.6	160.4 ± 21.8	276.2 ± 71.4	180.9 ± 16.8
Total clearance (mL/min/kg)	28.0 ± 2.8	35.3 ± 4.1	27.7 ± 4.1	32.8 ± 4.2

Values are presented as the mean \pm standard error. C_{max} , peak plasma concentration; t_{max} , time of C_{max} ; $t_{1/2}$, elimination half-life; AUC, area under the plasma concentration-time curve.

Scavone JM et al. J Clin Pharmacol. 1998;38:603-609.

GSA National Summit on OTC Sleep Aids and Sleep Health in Older Adults



Pharmacokinetics Comparison Across Studies



Comparison of Pharmacokinetic Variables for Diphenhydramine Among Published Studies

		mine		
Reference	Vd (L/kg)*	Half-life (hr)*	Clearance (mL/min/kg)*	Oral Bioavailability
Albert, et al ² (N = 2)	_	5.6	_	0.50†
Carruthers, et al ³ (N = 6)	3.29	3.3	11.2	0.43
Berlinger, et al ⁴ (N = 5) Spector, et al ⁵	4.17	4.1	12.1	0.61
Meredith, et al ⁶ (N = 8)	8.04	9.3	9.8	-
Present study (N = 10)	4.54	8.4	6.2	0.72

*Kinetic variables after intravenous dosage; †approximation. Vd = volume of distribution; N = number of subjects.

Blyden GT et al. J Clin Pharmacol. 1986;26:529-533.

GSA National Summit on OTC Sleep Aids and Sleep Health in Older Adults


20 Agents With Greatest M1/H1 Binding Affinity Ratio That Cross BBB (Highest Ratio of M1/H1 Inhibition Constants)

Agent	Approximate H1/M1 Binding Affinity	Comments
Pyrilamine	130,000	Highly selective H1 antagonist available OTC for cold and menstrual symptoms
Mirtazapine	5000	Highly selective H1; was in insomnia development by Organon; now Merck owned
Methapyrilene	1800	Was in OTC sleep aides until caused liver cancer in rats with long-term use
Dimethindene	700	S-Isomer potent M2 antagonist; R Isomer responsible for H1 antagonism
Hydroxyzine	590	Relatively low potency anti-H1 with relatively low M1; probably dosed > than needed
Trazodone	550	Low potency anti-H1 with minimal M1; most potent for NE, 5HT2, 5HTT blockade
Doxepin	330	Highly selective H1; Somaxon recently received FDA insomnia indication for 3-6 mg
Tripelennamine	230	Available OTC and often combined with cold medications; relatively H1 selective
Carbinoxamine	220	FDA approved for allergy, vasomotor rhinitis; mild urticaria; angioedema, low anti-M1
Tripelenamine	180	Relatively weak H1; very low M1 antagonism
Isothipendyl	180	Very selective H1 antagonist; Available for allergy and as topical antipruritic
Pyrathiazine	170	Closely related to promethazine; Moderate selectivity
Chlorpheniramine	120	OTC anti-H1; relatively H1 selective; also delayed release; Pregnancy Cat B
Clemastine	62	OTC anti-H1; potent M1; moderate selectivity; long T1/2; Pregnancy Cat B
Alimemazine	53	Somewhat selective; not available in U.S.; antipruritic, anti-emetic; allergy, sedation.
Doxylamine	40	Weak H1 antagonist but no Ach blockade and minimal others; Pregnancy Cat B
Meclizine	26	Very weak H1; very low anti-Ach; used for vertigo/motion sickness
Diphenylpyraline	24	Marketed in Europe for allergy; potent M1 blocker; also dopamine reuptake inhibitor
Diphenhydramine	20	Weak H1 antagonist but low Ach blockade and minimal others; Pregnancy Cat B

Kubo N et al. Jpn J Pharmacol. 1987;43:277e82.

Richelson E. Mayo Clin Proc. 2001;76:511-527.

GSA National Summit on OTC Sleep Aids and Sleep Health in Older Adults



SAS-0 Patients' Da	GLM Cro aily Ques				3)	
				F-Rat	io	-
		Drug	Placebo	Treatment	Period	
How long did it take you to fall asleep? (0-4)	Week 1 Week 2	2.07 2.36	1.68 2.05	9.07**	8.05**	_
How many times did you wake up during night? (0–4)	Week 1 Week 2	2.86 3.15	2.68 2.89	9.69**	12.52***	
Time spent awake in bed? (0–6)†	Week 1 Week 2	1.44 1.04	1.84 1.60	13.84***	5.96*	
How many hours did you sleep? (0-4)	Week 1 Week 2	1.92 2.21	1.68 1.66	18.77***	2.18	
How much did medica- tion help you sleep? (0-3)	Week 1 Week 2	1.24 1.53	0.92 0.82	21.95***	0.83	
How deeply did you sleep? (0-3)	Week 1 Week 2	2.12 2.26	1.82 1.94	22.95***	4.13*	
How was the quality of your sleep? (0-4)	Week 1 Week 2	2.71 2.90	2.39 2.53	16.96***	4.26*	
How rested did you feel when you woke up? (0-3)	Week 1 Week 2	1.96 2.07	1.86 1.89	6.15*	1.64	

Variable	Valerian-Hops	Group Placebo	Diphenhy- dramine
		Sleep Latency, m	
Sleep diary			
Baseline	35.07 (25.79) 59	27.88 (20.96) 65	25.69 (13.73) 60
Week 2	27.54 (25.02)	23.77 (21.49)	21.62 (12.87)
Week 4	25.89 (28.10)	23.71 (21.19)	22.11 (13.83)
Week 6	25.71 (25.48)	24.50 (17.90)	20.70 (13.80)
Polysomnog	raphy		
Baseline	19.48 (21.61) 22	36.04 (43.30) 26	17.77 (19.40) 26
Week 1	15.94 (17.69)	19.50 (29.25)	15.65 (22.64)
Week 2	9.06 (4.95)	18.35 (22.82)	10.46 (9.57)

	Valerian	Placebo	Diph 50 mg
		Sleep Efficiency,	%
Sleep diary		D 00	
Baseline	81.32 (8.84) 58	80.13 (9.81) 65	82.59 (7.30) 58
Week 2	84.32 (9.68)	82.57 (11.53)	87.17 (6.55)
Week 4	86.37 (10.17)	83.38 (10.14)	85.62 (8.30)
Week 6	85.00 (10.48)	82.92 (9.67)	86.96 (6.90)
Polysomnog	raphy		
Baseline	76.33 (20.39) 22	75.76 (14.62) 26	77.34 (17.77) 26
Week 1	84.97 (13.13)	80.83 (15.84)	84.30 (9.01)
Week 2	84.68 (10.54)	83.72 (10.56)	86.31 (10.94)
Aorin CM et al. <i>Sleep</i>	p. 2005;28:1465-1471.		

Efficacy	of Din	henhv	dramine	and \	/alerian
LINCAC		I CITITY	arannic		archan



	Valerian	Placebo	Diph 50 mg
		Total Sleep Time	(min)
Sleep diary			
Baseline	392.91 (67.66) 58	384.46 (74.71) 65	389.99 (74.95) 58
Week 2	404.88 (67.14)	401.76 (78.35)	419.59 (60.62)
Week 4	418.82 (66.49)	405.75 (71.07)	399.96 (77.04)
Week 6	411.06 (73.62)	399.17 (76.74)	412.85 (82.10)
Polysomnogra	aphy		
Baseline	340.69 (98.29) 22	335.02 (61.17) 26	347.93 (82.73) 26
Week 1	373.73 (65.01)	362.69 (74.80)	375.21 (41.09)
Week 2	381.36 (65.95)	370.40 (45.49)	382.77 (49.21)
Morin CM et al. Sleep.	2005;28:1465-1471.		
GSA Nationa	al Summit on OTC Sleep	Aids and Sleep Health in	Older Adults

Efficacy o	f Temazepam and Diphenhydramine
in Elderly	Adults With Sleep Problems

Table 3.	Results	of Morning	Questionnaire
----------	---------	------------	---------------

QUESTION*	TEMAZEPAM	DPH	PLACEBO
1 (latency)	1.84†	2.201	1.80
2 (duration)	1.74	2.15	1.87
3 (number of awakenings)	1.97	2.01	1.90
4 (time spent awake)	1.76	2.04	1.84
5 (overall evaluation)	1.91	2.14	1.83
6 (overall evaluation)	2.66	2.72	2.36


*See Table 1 for wording of questions and meaning of numerical results.


†Different from placebo p < 0.05. DPH = diphenhydramine.


Meuleman JR et al. Drug Intell Clin Pharmacol. 1987;21:716-720.


GSA National Summit on OTC Sleep Aids and Sleep Health in Older Adults

Safety in Elder	ly Adı	ılts		DT AND N	C SLEEP AIDS SLEEP NEALTH OLDER ADULIS
Table 4. Te	sts of Neur	ologic Fu	nction		
NEUROLOGIC TEST	TEMAZEPAM V	S. PLACEBO	DPH VS	PLACEBO	=
Word list Vocabulary		+		+	-
Tapping board		+	+	+	
Cancellation test-time	+		+		
Cancellation test- omissions		+		+	
Digit span forward		+		+	
Digit span reverse		+	+		
Digit symbol substitution	_	+		+	
Plus sign indicates better administered.	score on lest di	aring week v	when this	agent was	
Meuleman JR et al. Drug Intell Clin Pharma	col. 1987;21:716-7	20.			
GSA National Summit on OT	C Sleep Aids ar	nd Sleep Hea	alth in Ol	der Adults	











Grand Hyatt ● Washington, DC Wednesday and Thursday, October 16-17, 2013

Workgroup



Steven M. Albert, PhD, *Workgroup Chairperson,* is a Professor in the Graduate School of Public Health in the Department of Behavioral and Community Health Sciences at the University of Pittsburgh. He teaches courses on aging as a field of public health, the assessment of quality of life in health and aging, social dimensions of aging, evaluation, and a public health approach to long-term care. He is also the Chair for Research and Science.

Dr. Albert's research centers on the assessment of health outcomes in aging and chronic disease, including physical and cognitive function, health service use, and the cost of care, quality of life, and clinical decision making. His recent efforts include investigation of mental health and clinical decisions at the end of life (National Institute of Mental

Health) and a study of the cognitive and physical basis of independence in older people (National Institute on Aging). Dr. Albert's current projects include a study of worksite health promotion, modeling of vaccine refusal across the lifespan, and public health surveillance of the end of life. He has completed research on attitudes toward health promotion in culturally insular communities, challenges in assessing quality of life in people with cognitive impairment, and cognitive factors in medication adherence. During 2010-2014, his group is leading a statewide comparative effectiveness trial of primary prevention of falling in old age (Centers for Disease Control and Prevention) and an investigation of functional trajectories at the end of life (National Institute of Nursing Research). His ongoing studies involve medication reviews among older adults in senior housing (The Pittsburgh Foundation) and use of nasal ventilation (ALS Foundation).

During 2009-2011, Dr. Albert was the secretary/treasurer of the Behavioral and Social Sciences section of The Gerontological Society of America. He serves on the editorial boards for the *Journal of the American Medical Directors Association, Internet Journal of Mental Health, Preventive Medicine,* and *Journal of Aging Studies.* He is also a reviewer for the *Journal of Gerontology, The Gerontologist, American Journal of Public Health, Journal of the American Geriatrics Society, Neurology, Journal of Aging and Health, Journal of Cross-Cultural Gerontology, Journal of the American Medical Association,* and *Neuroepidemiology.*





Thomas Roth, PhD, is the Director of the Sleep Disorders and Research Center at Henry Ford Health System in Detroit. His research primarily focuses on sleep processes, including research on sleep loss, sleep fragmentation, and deviation from sleep processes such as pharmacological effects and sleep pathologies. In addition to his position at Henry Ford Health System, Dr. Roth is a Clinical Professor of Psychiatry at the University of Michigan School of Medicine in Ann Arbor.

Dr. Roth has held numerous leadership positions within the field of sleep disorders. His is a past chairman of the National Center on Sleep Disorders Research Advisory Board at the National Institutes of Health. He also is a past president of the United States Sleep Research Society, the American Sleep Disorders Association, and the

National Sleep Foundation. Dr. Roth has published over 380 manuscripts, 13 edited volumes, 176 chapters, and 515 abstracts; he also is a past editor in chief of the journal *Sleep*. He received his doctoral degree from the University of Cincinnati in 1970.



Michael Toscani, PharmD, is the Fellowship Administrator for the Rutgers Institute for Pharmaceutical Industry Fellowships and Adjunct Clinical Professor at the Ernest Mario School of Pharmacy. Dr. Toscani is also President of Clinical Solutionz and Consulting Medial Director for KOL, LLC, which are private health care consulting companies. He has held senior management positions in the pharmaceutical, contract research, and health and disease management industries for more than 25 years, and he is a frequent national speaker and author in both the scientific and health care management areas. He currently serves on the editorial boards of the *Journal of Population Health Management* and *Specialty Pharmacy*, and was on the editorial boards of the *Journal of Clinical Outcomes Management, Journal of Clinical Research and Pharmacoepidemiology,* and the *Journal of Osteopathic Medicine*.

Dr. Toscani's scholarly interests include clinical development of new pharmaceutical agents in multiple therapeutic areas; pharmaceutical industry trends; key opinion leader identification and management; the design and implementation of disease management initiatives focused on modifying patient behavior; value assessments; and outcomes studies evaluating the benefits of interventions on patient care. He is active in many charitable and nonprofit organizations. He currently serves as the president of the Central New Jersey Board of Advisors for the American Cancer Society and is the vice chairman of the Foundation Board for Thomas Edison State College. He is a past president and honorary board member of All Access Mental Health (AAMH), a community mental health treatment center in New Jersey. Dr. Toscani received his bachelor of science in pharmacy and doctor of pharmacy degrees from St. John's University College of Pharmacy, and he completed a 2-year postdoctoral research and teaching fellowship in infectious diseases at Hartford Hospital.





Michael V. Vitiello, PhD, is Professor of Psychiatry and Behavioral Sciences, Gerontology and Geriatric Medicine, and Biobehavioral Nursing, and he is Co-Director of the Center for Research on the Management of Sleep Disturbances and Co-Director of the Northwest Geriatric Education Center at the University of Washington in Seattle. He is an internationally recognized expert in sleep, circadian rhythms, and sleep disorders in aging. His research efforts, funded by the National Institutes of Health, focus on the causes, consequences, and treatments of disturbed sleep, circadian rhythms, and cognition in older adults. He is the author of over 450 scientific articles, reviews, chapters, editorials, and abstracts.

Dr. Vitiello is a member of the Board of Directors and the Scientific Program, a co-chair of the Society of Behavioral Sleep Medicine, a member of the Governing Council of the

World Sleep Federation, and serves as vice president of the International Sleep Science and Technology Association. He is a past president of both the Sleep Research Society and the Sleep Research Society Foundation, and past chair of the Sleep Disorders Research Advisory Board, National Institutes of Health. He has served as the Scientific Program chair of the Associated Professional Sleep Societies (American Academy of Sleep Medicine and Sleep Research Society), and on the Board of Directors of the National Sleep Foundation. He is a Fellow of The Gerontological Society of America and a founding member of the Society of Behavioral Sleep Medicine and the International College of Geriatric Psychoneuropharmacology. Dr. Vitiello is founding co-editor and editor in chief (for the Americas) of *Sleep Medicine Reviews*, and a member of the editorial boards of the *Journal of the American Geriatric Society* and *Sleep Medicine*. He has previously served on the editorial boards of *American Journal of Geriatric Psychiatry, Behavioral Sleep Medicine, Journal of Gerontology: Medical Sciences, Journal of Gerontology: Psychological Sciences*, and *Sleep*.



Phyllis C. Zee, MD, PhD, is Professor of Neurology, Neurobiology, and Physiology at Northwestern University. She is also Director of the Sleep Disorders Center and the Accreditation Council for Graduate Medical Education–accredited sleep medicine fellowship training program and Associate Director of the Center for Sleep and Circadian Biology. She earned a doctoral degree in physiology and biophysics and a medical degree from the Chicago Medical School in Illinois. As a National Institutes of Health (NIH) postdoctoral fellow, she conducted basic science studies on the effects of age on circadian rhythms and sleep.

Dr. Zee's career focus has been to translate basic and clinical science in sleep and circadian biology to the practice of neurology and sleep medicine. Her research

investigates the effects of age on sleep and circadian rhythms, genetic regulation of circadian sleep disorders, and behavioral interventions to improve sleep and performance. Her current NIH-sponsored research projects include studies to examine the ability of exercise to improve sleep and health in older people with insomnia, phenotypic characterization and genetic analysis of circadian rhythm sleep disorders, relationship between sleep, metabolic and cardiovascular risk, and the effects of age on the neural response to sleep loss. Dr. Zee is active on committees and panels both locally and nationally. She has been on the editorial boards of several journals and is currently an associate editor for the journal *Sleep*. Dr. Zee also is on the Board of Directors of the Sleep Research Society, the National Sleep Foundation, and is the chair of the NIH Sleep Disorders Research Advisory Board.





Morris Lewis, MBA, is Senior Director of External Affairs at Pfizer Consumer Healthcare. He began his career at Pfizer, Inc. in 2003, and led Pfizer's Medicare Part D commercial effort from 2003 to 2008. Thereafter, until joining Pfizer Consumer Health in 2010, Mr. Lewis led public affairs efforts across Pfizer's branded prescription medications. Prior to joining Pfizer, he was involved for 10 years as a consultant to the pharmaceutical industry, primarily on the topics of managed care and disease management; he also spent a number of years in other health care industry positions. Mr. Lewis holds a master of business administration from the Wharton School of Business at the University of Pennsylvania and undergraduate degrees from Washington and Lee University.





Grand Hyatt ● Washington, DC Wednesday and Thursday, October 16-17, 2013

Reactor Panel



Joan Enstam Baird, PharmD, CGP, FASCP, is the Director of Clinical Affairs for the American Society of Consultant Pharmacists (ASCP) in Alexandria, Virginia. She serves as a resource to ASCP members and staff on issues related to clinical practice and oversees all ASCP activities pertaining to clinical affairs.

Previously, Dr. Baird's work in geriatric pharmaceutical care included consulting and dispensing for two national pharmaceutical services companies. She also has been a clinical pharmacy specialist for two state mental health facilities on the eastern shore of Maryland. Her administrative experience includes work as the program

coordinator for the Mental Health Program at the University of Maryland Baltimore School of Pharmacy, where she developed and presented usage reports at the statewide Pharmacy and Therapeutics Committee meetings. These data were used to educate prescribers at the state psychiatric facilities about appropriate use of antipsychotic medications, with an emphasis on reducing polypharmacy through dosage optimization and stepwise prescribing regimens.

Dr. Baird has been an active member of ASCP since 2005. She has participated in the planning and execution of state conferences and other events for the Maryland Chapter of ASCP and has served as the chapter's membership director. She has lectured on safe medication prescribing to geriatric patients to both nursing students and the general public, and has served as an adjunct faculty member of the University of Maryland Eastern Shore School of Pharmacy.



Deborah A. DiGilio, MPH, is the Director of the American Psychological Association Office on Aging. The office promotes the application of psychological science and practice to address the needs and support the strengths of older adults, their families, and caregivers. Her current efforts focus on increasing the availability of mental health services for older adults, building the psychology and aging workforce through expanded education and training opportunities, public education, and advocating for policies that promote positive aging and address the needs of older adults with mental and behavioral health disorders. Ms. DiGilio has worked in the health and aging field for over 30 years, including positions with



George Mason University, AARP, the American Public Health Association, and Kaiser Permanente of the Mid-Atlantic States. Ms. DiGilio is currently on the Board of Directors of the National Alliance for Caregiving and the Coordinating Council of the Eldercare Workforce Alliance, and she is a past chair of the National Coalition on Mental Health and Aging.



James A. Owen, PharmD, BCPS, is the Associate Vice President of Practice and Science Affairs at the American Pharmacists Association (APhA), the national professional society of pharmacists headquartered in Washington, DC. He manages APhA's practice affairs activities including medication therapy management projects and services, directs activities and projects for the APhA Community Pharmacy Residency Program initiative, oversees activities for APhA's Practice and Science Academies, and participates in activities associated with medication safety and quality improvement.

Prior to joining APhA, Dr. Owen was the Director of Clinical Services and Professional Development for Happy Harry's Inc., a regional chain pharmacy organization based in Newark, Delaware, where he developed and initiated clinical service programs, directed activities for training of pharmacy staff, and provided community outreach. His background includes 17 years of experience in community pharmacy practice as a staff pharmacist, pharmacy manager, preceptor, and community pharmacy residency director. Dr. Owen continues to practice parttime as a health-system inpatient pharmacist.

He graduated from the Philadelphia College of Pharmacy and Science with a bachelor of science in pharmacy in 1990 and earned his doctor of pharmacy degree from the Massachusetts College of Pharmacy and Health Sciences in 2007. He is Board Certified in Pharmacotherapy by the Board of Pharmacy Specialties.





Grand Hyatt ● Washington, DC Wednesday and Thursday, October 16-17, 2013

Participants

Steven Albert

Professor of Behavioral and Community Health Sciences University of Pittsburgh smalbert@pitt.edu

Joan Baird

Director of Clinical Affairs American Society of Consultant Pharmacists jbaird@ascp.com

Inne Barber

Senior Director of Community Partnerships National Sleep Foundation ibarber@sleepfoundation.org

Rosemary Blieszner

President-elect The Gerontological Society of America rmb@vt.edu

Ray Bullman

Executive Vice President National Council on Patient Information and Education bullman@ncpie.info

Tom Clifford Director of Development National Sleep Foundation tclifford@sleepfoundation.org

Yanira Cruz

President and Chief Executive Officer National Hispanic Council on Aging ycruz@nhcoa.org

Deborah DiGilio

Director, Office on Aging American Psychological Association ddigilio@apa.org

Sarah Dunnicliff

Program Manager National Sleep Foundation sdunnicliff@sleepfoundation.org

Christine Harding

Director of Community Education National Council on Aging christine.harding@ncoa.org

Marcia Howard

Senior Director of Regulatory and Scientific Affairs Consumer Healthcare Products Association mhoward@chpa.org

Dominique Kelly

Clinical Research Physician Pfizer Consumer Healthcare Dominique.Kelly@pfizer.com



Salma Lemtouni Medical Officer Food and Drug Administration salma.lemtouni@fda.hhs.gov

Morris Lewis

Senior Director, External Affairs Pfizer Consumer Healthcare morris.lewis@pfizer.com

Judy Lofton Medical Writer jclofton@verizon.net

James Owen

Associate Vice President of Practice and Science Affairs American Pharmacists Association jowen@aphanet.org

Tom Roth

Director of Research and Division Head Henry Ford Health Systems troth1@hfhs.org

Jay Sirois

Director of Regulatory and Scientific Affairs Consumer Healthcare Products Association jSirois@chpa.org

Michael Toscani

Adjunct Clinical Professor/Fellowship Administrator Ernest Mario School of Pharmacy miket@rutgers.pharmacy.edu

Michael Vitiello

Professor of Psychiatry and Behavioral Sciences University of Washington vitiello@u.washington.edu

Nancy White

Director of Public Relations: Expertise Advocacy and Traffic Safety American Automobile Association NWhite@national.aaa.com

Kaitlyn Whiton

Program Manager National Sleep Foundation kwhiton@sleepfoundation.org

Mark Wingertzahn

Head of Global Clincial Research Pfizer Consumer Healthcare mark.wingertzahn@pfizer.com

Phyllis Zee

Professor of Neurology, Neurobiology, and Physiology Northwestern University phylliszee@gmail.com

GSA and Facilitation Team

James Appleby Executive Director and Chief Executive Officer

Carly Bushong Meetings and Education Manager

Judy Klein Facilitator Judie Lieu Senior Director of Innovation

Annette Schmidt

Senior Director of Strategic Alliance and Business Development

Kim Wolfe Facilitator

